The feasibility of assaying plasma phosphorylated tau protein (threonine 181), denoted p-tau181, using immunomagnetic reduction (IMR) is explored. The reagent for assaying p-tau181 with IMR was synthesized, and its analytic performances were characterized. Seventy-three subjects were recruited. Each participant was examined with neuropsychological tests, magnetic resonance imaging, and IMR assay for plasma p-tau181. Using commercially available IMR kits, the plasma total tau protein (T-tau) of each subject was assayed. The dynamic range for assaying p-tau181 using IMR was 1.96×10-2 pg/ml to 104 pg/ml. There was no significant interference from total tau protein in the assay of p-tau181. The measured concentrations of plasma p-tau181 were 2.46±1.09 pg/ml for healthy controls, 4.41±1.85 pg/ml for MCI due to AD, and 6.14±1.59 pg/ml for very mild AD. Meanwhile, the measured concentrations of plasma T-tau were 18.85±10.16 pg/ml for healthy controls, 32.98±10.18 pg/ml for MCI due to AD, and 37.54±12.29 pg/ml for very mild AD. A significant difference in plasma p-tau181 was observed between healthy controls and MCI due to AD (p < 0.001) and between MCI due to AD and very mild AD (p < 0.001). However, for the plasma T-tau concentration, a significant difference existed only between healthy controls and MCI due to AD (p < 0.001). This implies that the plasma p-tau181 level is correlated more to AD severity than plasma T-tau is. Additionally, p-tau181 was observed as approximately 14% of T-tau in human plasma.
KatzmanR (1976) The prevalence and malignancy of Alzheimer disease: A major killer. Arch Neurol33, 217–218.
2.
RoccaWA, PetersenRC, KnopmanDS, HebertLE, EvansDE, HallKS, GaoS, UnverzagtFW, LangaKM, LarsonEB, WhiteLR (2011) Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement7, 80–93.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersHV, MontineTJ (2012) National institute on aging–Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
7.
TomlinsonBE, BlessedG, RothM (1970) Observations on the brains of demented old people. J Neurol Sci11, 205–242.
8.
IqbalGIK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM (1986) Microtubule-associated protein tau: A component of Alzheimer paired helical filaments. J Biol Chem261, 6084–6089.
9.
VandermeerenM, MerckenM, VanmechelenE, SixJ, van de VoordeA, MartinJJ, CrasP (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem61, 1828–1834.
10.
MoriH, HosodaK, MatsubaraE, NakamotoT, FuriyaY, EndohR, UsamiM, ShojiM, MaruyamaS, HiraiS (1995) Tau in cerebrospinal fluids: Establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett186, 181–183.
11.
TapiolaT, AlafuzoffI, HerukkaSK, ParkkinenL, HartikainenP, SoininenH, PirttiläT (2009) Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol66, 382–389.
ArrigadaPA, GrowdonJH, Hedley-WhiteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel durationand severity of. Neurology42(3 Pt 1), 631–639.
14.
ParnettiL, LanariA, AmiciS, GallaiV, VanmechelenE, HulstaertF (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Neurol Sci22, 77–78.
15.
IshiguroK, OhnoH, AraiH, YamaguchiH, UrakamiK, ParkJM, SatoK, KohnoH, ImahoriK (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci Lett270, 91–94.
16.
KohnkenR, BuergerK, ZinkowskiR, MillerC, KerkmanD, DeBernardisJ, ShenJ, MöllerHJ, DaviesP, HampelH (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci Lett287, 187–190.
17.
HuYY, HeSS, WangX, DuanQH, Grundke-IqbalI, IqbalK, WangJ (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: An ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol160, 1269–1278.
18.
ThomannPA, KaiserE, SchönknechtP, PantelJ, EssigM, SchröderJ (2009) Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci34, 136–142.
19.
MeredithJEJr, SankaranarayananS, GussV, LanzettiAJ, BerishaF, NeelyRJ, SlemmonJR, PorteliusE, ZetterbergH, BlennowK, SoaresH, AhlijanianM, AlbrightCF (2013) Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease. PLoS One8, e76523.
20.
RavagliaS, BiniP, SinforianiE, FranciottaD, ZardiniE, ToscaP, MogliaA, CostaA (2008) Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer’s disease and vascular dementia. Neurol Sci29, 417–423.
21.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Neurology6, 131–144.
22.
MalnarM, KosicekM, BeneR, TarnikIP, PavelinS, BabicI, Brajenovic-MilicB, HecimovicH, TitlicM, TrkanjecZ, DemarinV, HecimovicS (2012) Use of cerebrospinal fluid biomarker analysis for improving Alzheimer’s disease diagnosis in a non-specialized setting. Acta Neurobiol Exp72, 264–271.
23.
KandimallaRJL, PrabhakarS, WaniWY, KaushalA, GuptaN, SharmaDR, GroverVK, BhardwajN, JainK, GillKD (2013) CSF p-Tau levels in the prediction of Alzheimer’s disease. Biol Open2, 1119–1124.
24.
ZetterbergH, WilsonD, AndreassonU, MinthonL, BlennowK, RandallJ, HanssonO (2013) Plasma tau levels in Alzheimer’s disease. Alzheimers Res Therapy5, 91–3.
25.
ChiuMJ, ChenYF, ChenTF, YangSY, YangFPG, TsengTW, ChiehJJ, ChenJCR, TzenKY, HuaMS, HorngHE (2014) Plasma tau as a window to the brain—Negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer’s disease. Hum Brain Mapp35, 3132–3142.
TzenKY, YangSY, ChenTF, ChengTW, HorngHE, WenHP, HuangYY, ShiueCY, ChiuMJ (2014) Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer’s disease. ACS Chem Neurosci5, 830–836.
TatebeH, KasaiT, OhmichiT, KishiY, KakeyaT, WaragaiM, KondoM, AllsopD, TokudaT (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: Pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol Neurodegener12, 631–11.
32.
YangSY, ChiuMJ, ChenTF, LinCH, JengJS, TangSC, LeeYF, YangCC, LiuBH, ChenHH, WuCC (2017) Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases. Sci Rep7, 9304.
33.
de jongD, JansenRWMM, KremerBPH, VerbeekMM (2006) Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. J Gerontol A Biol Sci Med Sci61A, 755–758.
34.
FaganAM, RoeCM, XiongC, MintunMA, MorrisJC, HoltzmanDM (2007) Cerebrospinal fluid tau/β-Amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol64, 343–349.
